Scholarlink

Purpose <p>To evaluate the safety of subthreshold laser treatment (SLT) at the level of the choriocapillaris (CC) using optical coherence tomography angiography (OCTA) in patients affected by intermediate age-related macular degeneration (iAMD).</p> Methods <p>This is an analysis of patients included in the PASCAL clinical trial, including iAMD patients with reticular pseudodrusen (RPD). OCTA imaging was performed at baseline, 1-month, and 3-month follow-ups, focusing on a 3 × 3-mm treated area. The CC slab was segmented and analyzed quantitatively for flow voids using the Phansalkar binarization method. Flow voids in the treated area were compared to no-treated areas and analyzed across time points.</p> Results <p>20 patients (20 eyes) were included in the study. No significant differences in CC flow voids (%) were observed between treated and no-treated areas at baseline (27.9% vs. 24.6%, p = 0.641), nor were significant changes noted over time in treated areas (baseline: 27.9%, 1-month: 28.8%, 3-month: 32.6%, p = 0.115). Similarly, no-treated areas exhibited no significant alterations over time (baseline: 24.1%, 1-month: 24.3%, 3-month: 26.8%, p = 0.204).</p> Conclusion <p>SLT did not induce detectable CC damage or alter perfusion in treated areas, further confirming its safety in managing RPD secondary to dry AMD. These findings support SLT as a viable therapeutic option, warranting further investigation to validate its long-term efficacy and safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Subthreshold laser treatment does not change choriocapillaris perfusion in patients with intermediate age-related macular degeneration

  • 期刊论文

  • 发表日期：

    2025年8月16日

查看全文
  • Riccardo Sacconi,
  • Matteo Menna,
  • Simone Marra,
  • Federico Beretta,
  • Francesco Bandello,
  • Giuseppe Querques

摘要

Purpose

To evaluate the safety of subthreshold laser treatment (SLT) at the level of the choriocapillaris (CC) using optical coherence tomography angiography (OCTA) in patients affected by intermediate age-related macular degeneration (iAMD).

Methods

This is an analysis of patients included in the PASCAL clinical trial, including iAMD patients with reticular pseudodrusen (RPD). OCTA imaging was performed at baseline, 1-month, and 3-month follow-ups, focusing on a 3 × 3-mm treated area. The CC slab was segmented and analyzed quantitatively for flow voids using the Phansalkar binarization method. Flow voids in the treated area were compared to no-treated areas and analyzed across time points.

Results

20 patients (20 eyes) were included in the study. No significant differences in CC flow voids (%) were observed between treated and no-treated areas at baseline (27.9% vs. 24.6%, p = 0.641), nor were significant changes noted over time in treated areas (baseline: 27.9%, 1-month: 28.8%, 3-month: 32.6%, p = 0.115). Similarly, no-treated areas exhibited no significant alterations over time (baseline: 24.1%, 1-month: 24.3%, 3-month: 26.8%, p = 0.204).

Conclusion

SLT did not induce detectable CC damage or alter perfusion in treated areas, further confirming its safety in managing RPD secondary to dry AMD. These findings support SLT as a viable therapeutic option, warranting further investigation to validate its long-term efficacy and safety.